Related Experiment Video
Updated: Jun 15, 2026
10:36
Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
Published on: March 17, 2016
Estrogen receptor regulates E2F1 expression to mediate tamoxifen resistance
Maggie C Louie1, Ashley McClellan, Christina Siewit
1Department of Natural Sciences and Mathematics, Dominican University of California, San Rafael, CA 94901, USA. maggie.louie@dominican.edu
Molecular Cancer Research : MCR
|March 11, 2010
Summary
Acquired antiestrogen resistance in breast cancer cells involves increased estrogen receptor alpha/Sp-1 interaction. This interaction enhances E2F1 expression, promoting tamoxifen resistance and tumor growth.
Area of Science:
- Oncology
- Molecular Biology
- Endocrinology
Background:
- Antiestrogen therapies like tamoxifen are crucial for breast cancer treatment but often face resistance.
- Understanding the mechanisms of acquired antiestrogen resistance is vital for developing effective targeted therapies.
Purpose of the Study:
- To establish and characterize a tamoxifen-resistant breast cancer cell line (MCF-7TamR).
- To investigate the molecular mechanisms underlying tamoxifen resistance, focusing on estrogen receptor (ER) signaling and cell cycle regulation.
Main Methods:
- Established a tamoxifen-resistant MCF-7 cell line (MCF-7TamR) through prolonged tamoxifen exposure.
- Characterized cell proliferation and cell cycle progression under various conditions (normal, hormone-deprived, tamoxifen-treated).
- Performed molecular analyses to assess the expression of key proteins (cyclin E1, cdk2, ACTR, E2F1) and estrogen receptor (ER) interactions.
Main Results:
- MCF-7TamR cells exhibited continuous growth in the presence of tamoxifen and increased S-phase entry.
- Resistant cells showed elevated expression of cyclin E1, cdk2, ACTR, and E2F1.
- ER degradation using Faslodex (ICI 182,780) reduced proliferation and E2F1 expression in resistant cells.
- Tamoxifen enhanced ERalpha/Sp-1 interaction and recruitment to the E2F1 promoter in resistant cells.
Conclusions:
- Tamoxifen resistance in breast cancer is partly mediated by estrogen receptor (ER) signaling.
- Increased ERalpha/Sp-1 interaction enhances E2F1 expression, contributing to tamoxifen resistance.
- Targeting ERalpha/Sp-1 interaction or E2F1 may offer new therapeutic strategies for overcoming tamoxifen resistance.
Related Concept Videos
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
01:31Transducer Mechanism: Nuclear Receptors
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
02:23Master Transcription Regulators
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:22Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
01:52Eukaryotic Transcription Inhibitors
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...